Early Airway Response to Allergen in Asthmatics (MK-0000-176)

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the Early Airway Response (EAR) associated change in forced expiratory volume in one second (FEV1) and plasma 9α-11ß-PGF2 ('9P') after single dose pretreatment of nedocromil, montelukast, and mometasone.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Mometasone Furoate; Montelukast; Nedocromil

Criteria

Inclusion Criteria:

• History of mild to moderate Asthma

• In good general health (except for asthma)

• Stable and free of respiratory infection

• Nonsmoker

• Females highly unlikely to conceive (surgically sterilized, postmenopausal, or agrees to use 2 acceptable methods of birth control)

Exclusion Criteria:

• Nursing mother

• Recent or ongoing upper or lower respiratory tract infection

• Unable to refrain from or anticipates the use of any prescription and non-prescription drugs

• Consumes excessive amounts of alcohol or caffeine

• History of stroke, chronic seizures, or major neurological disorder

• History of cancer

• Received a vaccination within the past 3 weeks